Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis

Patent metadata

Field	Value
Publication number	US-9765020-B2
Application number	US-201314533131-A
Country	US
Kind code	B2
Filing date	May 19, 2013
Priority date	May 23, 2012
Publication date	Sep 19, 2017
Grant date	Sep 19, 2017

Abstract

The invention relates to the compounds of

related compounds, or pharmaceutically acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucus diseases related to painful inflammation and ulceration of the digestive tract lining and in the mouth.

First claim

The invention claimed is:

1. A compound of Formula 1-1:

or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, or stereoisomer thereof.

2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 2 , wherein said pharmaceutical composition is formulated for oral administration, delayed release or sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration.

4. A method of treating mucositis, the method comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition of claim 3 .

5. The pharmaceutical composition of claim 2 , further comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and one or more carboxylic acid compounds selected from the group consisting of R-Lipoic acid, acetyl cysteine, caprylic acid, and salsalate.

6. The pharmaceutical composition of claim 5 , wherein the carboxylic acid compound is R-Lipoic acid.

7. The pharmaceutical composition of claim 5 , wherein the carboxylic acid compound is acetyl cysteine.

8. The pharmaceutical composition of claim 5 , wherein the carboxylic acid compound is caprylic acid.

9. The pharmaceutical composition of claim 5 , wherein the carboxylic acid compound is salsalate.

10. The pharmaceutical composition of claim 2 , further comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and one or more compounds selected from the group consisting of cysteamine, N-(2,6-dimethylphenyl)acetamide, mesalazine and pentoxifylline.

11. The pharmaceutical composition of claim 2 , further comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and cysteamine.

12. The pharmaceutical composition of claim 2 , further comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and mesalazine.

13. The pharmaceutical composition of claim 2 , further comprising a molecular conjugate of 2-(2,6-dichlorophenyl)guanidine and pentoxifylline.

Assignees

• Kandula Mahesh
• Cellix Bio Private Ltd

Inventors

• Kandula Mahesh

Classifications

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• C07C323/25

  the carbon skeleton being acyclic and saturated · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• C07C279/24 Primary

  Y being a hetero atom · CPC title

• C07D339/04

  having the hetero atoms in positions 1 and 2, e.g. lipoic acid · CPC title